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DISCUSSION
Dr Randolph Geary (Winston-Salem, NC). I would like to
commend the authors for bringing this to our attention and
reminding us of a serious and growing problem of premature
atherosclerosis in the HIV-AIDS population. I imagine we will all
be seeing a lot more of this in the future. I have always assumed that
the problem was related to dyslipidemia caused by protease inhib-
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itors, but the authors have convinced me there is a significant
contribution from the infection itself. By exposing vessel rings to
HIV Tat protein, they found significant endothelial cell dysfunc-
tion, and have gone on to prove that this is associated with
decreased nitric oxide synthase message and protein. So they
have implicated decreased nitric oxide production, but did not
measure nitric oxide directly or include L-arginine and L-NAME
controls.
Endothelial-dependent vasodilation is mediated not only by
nitric oxide, but can be affected by prostaglandin production and
cyclooxygenase. If Tat altered prostacyclin synthesis, then COX could
explain some of your findings. To get around this, did you include
indomethacin or another COX inhibitor in your bath solution? Also,
how does the dose of Tat that you employed relate to levels circulating
in HIV-AIDS? You used levels that were as high as 100 nmol/L, and
I suspect that this is somewhat supraphysiologic, considering most of
these patients will be on treatment and have fairly low viral loads with
very little HIV virus in the artery wall itself.
Dr Ramesh Paladugu. Thank you very much, Dr Geary, for
your comments.
First, we did not look at prostacyclin endothelial relaxing
factor. We just did nitric oxide eNOS measurements, and actually
this is the first time we did it, so next we are going to look at the
prostacyclin also.
The next one about the levels of the concentrations, usually
these are the levels which we took, 107, 109, 1011, from the
previous studies, but 107 is really high when patients are on
antiviral therapy. I totally agree with that.
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